BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, April 21, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2009

View Archived Issues

Teva submits BLA to FDA for XM-02 for chemotherapy-induced neutropenia

Read More

Kalbitor approved in U.S. for hereditary angioedema

Read More

Plethora Solutions and Columbia Laboratories execute marketing agreement for Striant SR

Read More

Acacia's subsidiary enters into license agreement with Boston Scientific

Read More

Ardea Biosciences reports results from combination trial of RDEA-594 and febuxostat

Read More

Pfizer and Astellas launch Caduet combination tablets in Japan

Read More

Sitaxentan reduces post-CPB acute kidney injury in porcine model

Read More

Phase III data reported for ticagrelor vs. clopidogrel in platelet aggregation

Read More

MK-1775 exhibits synergism with gemcitabine in pancreatic tumors in vivo

Read More

TRIN-2755 exhibits antitumor activity in multiple xenograft mouse models

Read More

Interim data presented from AV-412 phase I trial in advanced solid tumors

Read More

Data from phase I study on AS-703569 disclosed at 2009 AACR-NCI-EORTC meeting

Read More

Takeda reports results from first half of 2009 ended September 30

Read More

Merck KGaA describes TGF-beta receptor inhibitors as oncolytics

Read More

Advinus Therapeutics discloses novel adenosine receptor antagonists

Read More

Biovitrum discovers novel GPR119 agonists for the treatment of obesity

Read More

Novel antibacterial agents presented by Actelion

Read More

Keryx Biopharmaceuticals' perifosine receives FDA fast track designation

Read More

FDA lifts clinical hold of CytRx's arimoclomol in amyotrophic lateral sclerosis

Read More

DermaGen's antimicrobial peptide successful in phase I/IIa clinical trials in atopic dermatitis

Read More

GlaxoSmithKline files for approval of Rotarix vaccine in Japan

Read More

EMEA accepts clinical development plan for DiaPep-277

Read More

Vasopharm recruits first patient in a phase IIa trial of VAS-203

Read More

TiGenix completes acquisition of Orthomimetics

Read More

Wilex receives preliminary results of phase III Redectane trial

Read More

Hemispherx Biopharma receives FDA complete response letter for Ampligen NDA

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 20, 2026.
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • Brain and DNA

    Sex differences shape gene activity across the human brain

    BioWorld
    Genes that are switched on or off in the human brain differ between men and women. Moreover, these differences are not uniform. They vary across cortical regions...
  • Green arrow on blue abstract background

    Psychedelic space expanding on Trump’s EO

    BioWorld
    Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
  • Gilead Sciences patents new GTPase KRAS G12D inhibitors

    BioWorld Science
    Gilead Sciences Inc. has disclosed new GTPase KRAS G12D mutant inhibitors potentially useful for the treatment of cancer.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing